Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

Riancho-Zarrabeitia, L; Martinez-Taboada, V; Rua-Figueroa, I; Alonso, F; Galindo-Izquierdo, M; Ovalles, J; Olive-Marques, A; Fernandez-Nebro, A; Calvo-Alen, J; Menor-Almagro, R; Tomero-Muriel, E; Uriarte-Isacelaya, E; Botenau, A; Andres, M; Freire-Gonzalez, M; Soler, GS; Ruiz-Lucea, E; Ibanez-Barcelo, M; Castellvi, I; Galisteo, C; Vila, VQ; Raya, E; Narvaez-Garcia, J; Exposito, L; Hernandez-Beriain, JA; Horcada, L; Aurrecoechea, E; Pego-Reigosa, JM – 2020